ZymoGenetics is focused on the discovery and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and manufacturing organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, quality, drug formulation, process development and protein manufacturing.

ZymoGenetics Key Activities
Research: As part of the Bristol-Myers Squibb team, ZymoGenetics focuses its early research efforts on discovery and advancement of therapeutic proteins with potential applications in immuno-oncology diseases.

Manufacturing. ZymoGenetics also has core expertise and process development capabilities that it uses in early manufacturing of microbial and mammalian based proteins to support toxicology studies and early-stage clinical trials.
Through collaboration, cooperation and commitment, ZymoGenetics continues to help drive forward Bristol-Myers Squibb’s early pipeline.

Research Grants 18 show all


$162.3K
1984

Patents 4,105show all

  • 2,316
    C07K - Peptides
  • 1,875
    A61K - Preparations for medical, dental, or toilet purposes
  • 744
    C12N - Microorganisms or enzymes
  • 179
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 153
    A01K - Animal husbandry
  • 145
    C12Y - Enzymes
  • 74
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 73
    Y02A - Technologies for adaptation to climate change
  • 35
    A61L - Methods or apparatus for sterilising materials or objects in general
  • 30
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture

Clinical Trials 18show all

7N/A3Phase 12Phase 22Phase 32Phase 41Phase 1/Phase 21Phase 2/Phase 3

SEC Filings show all


80
8-K

26
10-Q

8
10-K

2
D

1
S-1

Contact Information

Seattle, WA
United States

SEC Form D Funding Events

DateOfferedSoldType
2008-11-17$15,510,000$15,510,000Option to Acquire, Security to be Acquired
2004-10-29Unknown Unknown Other (Paper Filing)

Key Executives

  • Bruce L.a. Carter, Ph.D.
    Executive Officer, Director
  • James A. Harper
    Director
  • Judith A. Hemberger, Ph.D.
    Director
  • David I. Hirsch, Ph.D.
    Director
  • Jonathan S. Leff
    Director
  • David H. MacCallum
    Director
  • Kurt Anker Nielsen
    Director
  • Edward E. Penhoet, Ph.D.
    Director
  • Lars Rebien Sorensen
    Director
  • Michael J. Dwyer
    Executive Officer
  • Heather L. Franklin
    Executive Officer
  • Darren R. Hamby
    Executive Officer
  • Vaughn B. Himes, Ph.D.
    Executive Officer
  • James A. Johnson
    Executive Officer
  • Nicole Onetto, M.D.
    Executive Officer
  • Suzanne M. Shema, J.D.
    Executive Officer
  • Douglas E. Williams, Ph.D.
    Executive Officer